Register Login

GYRE THERAPEUTICS, INC. (GYRE)

(10% Negative) GYRE THERAPEUTICS, INC. (GYRE) Announces Delay in included Trials for discovery Due to Geopolitical Situation, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Aug. 26, 2026, 1:01 p.m.

    📋 GYRE THERAPEUTICS, INC. (GYRE) - Clinical Trial Update

    Filing Date: 2026-08-26

    Accepted: 2026-08-26 09:00:44

    Event Type: Clinical Trial Update

    Event Details:

    GYRE THERAPEUTICS, INC. (GYRE) Announces Clinical Trial Update GYRE THERAPEUTICS, INC. (GYRE) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: included, operations
    • Diseases/Conditions: discovery
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Geopolitical Situation, Regulatory Process
    • Collaboration: Building A New Protein Degrader Company For Unmet Medical Needs
      • Targeting Payload Therapeutic-resistant PDX model Prostate cancer CDX model Non-human primate pilot toxicity Prostate cancer causes 35,000 – 36,500 death each year and is the second-leading cause of cancer death in the US. The Androgen Receptor (AR) acts as a critical oncogenic engine, driving prostate tumor growth, survival, and therapy resistance even after castration. Epigenetic factors are frequently mutated across human malignancies, including prostate cancer. Prior developments targeting epigenetic factors for prostate cancer has been limited by the toxicity. Protein degradation & cytotoxicity 19 CDK2 / Cyclin E TYK2 / JAK1 TRK DAC Fibrosis GSPT1 Commercial Foundation and Growth Opportunities with F351 (Hydronidone) ETUARYTM: The Commercial Anchor of Our Fibrosis Franchise Since 2011
      • Targeting GSPT1 for AML and Solid Tumor Cancers GSPT1 controls protein translation termination and plays important function for leukemia stem cells and tumor cells with MYC overproduction GSPT1 lacks an active site and is often considered “undruggable” Other programs targeting GSPT1 to develop a therapeutic showed insufficient therapeutic index. CG0093
      • Targeting TYK2 and JAK1 with a Degrader Broader Cytokine Coverage Higher and Broader Efficacy Potential Best-in-Class Opportunity TYK2 JAK1 + (Heterodimer) CDK2 / Cyclin E TYK2 / JAK1 TRK DAC Fibrosis GSPT1 CG6209

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: GYRE THERAPEUTICS, INC.
    • Ticker Symbol: GYRE

Search

News categories